KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$320.25
+1.16%Oct 15, 2026, 11:00 UTC
Krystal Biotech announced positive clinical data for KB113 in three patients with Gorlin syndrome, reporting regression in over 80% of assessed basal cell carcinoma lesions and histologically confirmed clearance of an injected lesion in each patient.
Source:Aug 3, 2026, 11:00 UTC
Krystal Biotech reported financial results for the second quarter ended June 30, 2026, with $119.2 million in global VYJUVEK revenue and $1.1 billion in cash and investments.